Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 2Melanoma 2Uterine Cervical Neoplasms 1Testicular Germ Cell Tumor 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 9Nivolumab 4tislelizumab 2spartalizumab 2budigalimab 2atezolizumab 2Ipilimumab 2venetoclax 1ruxolitinib 1rovalpituzumab tesirine 1poly ICLC 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1avelumab 1Sirolimus 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1LY2940680 1Injections 1Immunotherapy, Adoptive 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × milademetan × Dermatologic × Clear all
NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Rain Oncology Inc

Phase 1/2 Withdrawn
DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡